JP2017536380A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2017536380A5 JP2017536380A5 JP2017527848A JP2017527848A JP2017536380A5 JP 2017536380 A5 JP2017536380 A5 JP 2017536380A5 JP 2017527848 A JP2017527848 A JP 2017527848A JP 2017527848 A JP2017527848 A JP 2017527848A JP 2017536380 A5 JP2017536380 A5 JP 2017536380A5
- Authority
- JP
- Japan
- Prior art keywords
- pharmaceutical composition
- fibrosis
- composition according
- hepe
- drugs
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP2021192836A JP2022031813A (ja) | 2014-12-02 | 2021-11-29 | １５－ｈｅｐｅを含む組成物、およびそれを用いて線維症を処置または防止する方法 |
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201462086535P | 2014-12-02 | 2014-12-02 | |
| US62/086,535 | 2014-12-02 | ||
| PCT/US2015/063488 WO2016090030A1 (en) | 2014-12-02 | 2015-12-02 | Compositions comprising 15-hepe and methods of treating or preventing fibrosis using same |
Related Child Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2021192836A Division JP2022031813A (ja) | 2014-12-02 | 2021-11-29 | １５－ｈｅｐｅを含む組成物、およびそれを用いて線維症を処置または防止する方法 |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2017536380A JP2017536380A (ja) | 2017-12-07 |
| JP2017536380A5 true JP2017536380A5 (OSRAM) | 2019-01-24 |
| JP6986445B2 JP6986445B2 (ja) | 2021-12-22 |
Family
ID=56092410
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2017527848A Expired - Fee Related JP6986445B2 (ja) | 2014-12-02 | 2015-12-02 | １５−ｈｅｐｅを含む組成物、およびそれを用いて線維症を処置または防止する方法 |
| JP2021192836A Pending JP2022031813A (ja) | 2014-12-02 | 2021-11-29 | １５－ｈｅｐｅを含む組成物、およびそれを用いて線維症を処置または防止する方法 |
Family Applications After (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2021192836A Pending JP2022031813A (ja) | 2014-12-02 | 2021-11-29 | １５－ｈｅｐｅを含む組成物、およびそれを用いて線維症を処置または防止する方法 |
Country Status (17)
| Country | Link |
|---|---|
| US (1) | US10363235B2 (OSRAM) |
| EP (2) | EP3226873B1 (OSRAM) |
| JP (2) | JP6986445B2 (OSRAM) |
| KR (1) | KR20170102879A (OSRAM) |
| CN (2) | CN107206008A (OSRAM) |
| AU (2) | AU2015358512B2 (OSRAM) |
| BR (1) | BR112017011685A2 (OSRAM) |
| CA (1) | CA2968980A1 (OSRAM) |
| ES (1) | ES2900593T3 (OSRAM) |
| IL (2) | IL252431B (OSRAM) |
| MA (1) | MA41120A (OSRAM) |
| MX (2) | MX382116B (OSRAM) |
| PH (1) | PH12017501022B1 (OSRAM) |
| RU (2) | RU2020115523A (OSRAM) |
| SG (2) | SG11201704495VA (OSRAM) |
| WO (1) | WO2016090030A1 (OSRAM) |
| ZA (2) | ZA201704463B (OSRAM) |
Families Citing this family (7)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| GB201301626D0 (en) * | 2013-01-30 | 2013-03-13 | Dignity Sciences Ltd | Composition comprising 15-OHEPA and methods of using the same |
| EP3878835A1 (en) | 2013-11-15 | 2021-09-15 | DS Biopharma Limited | Pharmaceutically acceptable salts of polyunsaturated hydroxy fatty acids |
| US20150196521A1 (en) * | 2014-01-10 | 2015-07-16 | Dignity Sciences Limited | Pharmaceutical compositions comprising 15-hepe and methods of treating asthma and lung disorders using same |
| JP2018502163A (ja) * | 2015-01-16 | 2018-01-25 | アフィミューン リミテッド | １５−ｈｅｐｅを含む組成物及びそれを使用する方法 |
| WO2016181221A1 (en) | 2015-05-13 | 2016-11-17 | Dignity Sciences Limited | Compositions comprising 15-oxo-epa or 15-oxo-dgla and methods of making and using same |
| CA3008774C (en) * | 2015-12-18 | 2021-10-12 | Afimmune Limited | Compositions comprising 15-hepe and methods of using the same |
| US20210315851A1 (en) | 2020-04-03 | 2021-10-14 | Afimmune Limited | Compositions comprising 15-hepe and methods of treating or preventing hematologic disorders, and/or related diseases |
Family Cites Families (27)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US6180671B1 (en) * | 1998-03-10 | 2001-01-30 | Beth Israel Deaconess Medical Center, Inc. | Methods for treating disorders in which docosahexaenoic acid (DHA) levels are affected |
| JP2000191525A (ja) | 1998-12-25 | 2000-07-11 | Nof Corp | 皮膚外用剤組成物 |
| WO2001049282A2 (en) * | 2000-01-06 | 2001-07-12 | Martek Biosciences Corporation | Therapeutic preparations of highly unsaturated fatty acids |
| CN1202068C (zh) | 2000-02-16 | 2005-05-18 | 布里格姆及妇女医院股份有限公司 | 阿司匹林触发的脂质介体 |
| JP2005179211A (ja) | 2003-12-17 | 2005-07-07 | Idemitsu Kosan Co Ltd | 皮膚外用剤組成物 |
| US20070105954A1 (en) | 2003-12-31 | 2007-05-10 | Ingennus Limited | Formulation containing a carboxylic acid or an ester thereof |
| US20050239889A1 (en) | 2004-04-26 | 2005-10-27 | Jean Gosselin | In vivo release of endogenous anti-microbial mediators by leukotriene B4 (LTB4) administration |
| CA2662987A1 (en) * | 2006-08-08 | 2008-02-21 | Tethys Bioscience, Inc. | Markers of non-alcoholic fatty liver disease (nafld) and non-alcoholic steatohepatitis (nash) and methods of use thereof |
| US8042070B2 (en) * | 2007-10-23 | 2011-10-18 | International Business Machines Corporation | Methods and system for analysis and management of parametric yield |
| GB0802116D0 (en) * | 2008-02-05 | 2008-03-12 | Natural Enviromental Res Counc | Treatment |
| PE20100156A1 (es) * | 2008-06-03 | 2010-02-23 | Boehringer Ingelheim Int | Tratamiento de nafld |
| WO2009154230A1 (ja) | 2008-06-17 | 2009-12-23 | 持田製薬株式会社 | 非アルコール性脂肪肝炎の予防／改善・治療薬 |
| WO2010120880A1 (en) * | 2009-04-14 | 2010-10-21 | Vertex Pharmaceuticals Incorporated | Treatment of liver diseases with a caspase inhibitor |
| GB0907413D0 (en) | 2009-04-29 | 2009-06-10 | Equateq Ltd | Novel methods |
| US10154977B2 (en) | 2011-03-25 | 2018-12-18 | The Brigham And Women's Hospital, Inc. | Anti-inflammatory particles |
| US20120264824A1 (en) * | 2011-04-15 | 2012-10-18 | Mochida Pharmaceutical Co., Ltd. | Compositions and methods for treating non-alcoholic steatohepatitis |
| US8658787B2 (en) * | 2011-09-16 | 2014-02-25 | Galectin Therapeutics Inc. | Galacto-rhamnogalacturonate compositions for the treatment of non-alcoholic steatohepatitis and non-alcoholic fatty liver disease |
| JP2014530841A (ja) | 2011-10-19 | 2014-11-20 | ディグニティサイエンシスリミテッド | Ｄｇｌａおよび／または１５−ｈｅｔｒｅを含む医薬組成物、ならびにその使用方法 |
| US8293790B2 (en) | 2011-10-19 | 2012-10-23 | Dignity Sciences Limited | Pharmaceutical compositions comprising DGLA and benzoyl peroxide and methods of use thereof |
| CA2856715A1 (en) | 2011-11-29 | 2013-06-06 | Dignity Sciences Limited | Compositions comprising 20-carbon fatty acids and methods of making and using same |
| CN104302305A (zh) * | 2011-12-16 | 2015-01-21 | 塔瑞克斯制药有限公司 | 用于治疗纤维化的血管紧张素 |
| US20120264705A1 (en) | 2012-01-26 | 2012-10-18 | Dignity Sciences Limited | Antimicrobial compositions comprising 15-hetre and methods of use thereof |
| US20130267598A1 (en) | 2012-02-23 | 2013-10-10 | Dignity Sciences Limited | Pharmaceutical compositions comprising dgla, 15-ohepa, and/or 15-hetre and methods of reducing sebum production using same |
| EP4205546A1 (en) | 2012-05-10 | 2023-07-05 | Solutex NA LLC | Oils with anti-inflammatory activity containing natural specialized proresolving mediators and their precursors |
| GB201301626D0 (en) | 2013-01-30 | 2013-03-13 | Dignity Sciences Ltd | Composition comprising 15-OHEPA and methods of using the same |
| TWI742541B (zh) * | 2013-03-15 | 2021-10-11 | 英商邊緣生物科技有限公司 | 用於治療肺纖維化、肝纖維化、皮膚纖維化及心臟纖維化之經取代之芳族化合物 |
| CA3008774C (en) | 2015-12-18 | 2021-10-12 | Afimmune Limited | Compositions comprising 15-hepe and methods of using the same |
-
2015
- 2015-12-01 MA MA041120A patent/MA41120A/fr unknown
- 2015-12-02 ES ES15865150T patent/ES2900593T3/es active Active
- 2015-12-02 AU AU2015358512A patent/AU2015358512B2/en not_active Ceased
- 2015-12-02 EP EP15865150.5A patent/EP3226873B1/en active Active
- 2015-12-02 EP EP21200516.9A patent/EP3988101A1/en not_active Withdrawn
- 2015-12-02 RU RU2020115523A patent/RU2020115523A/ru unknown
- 2015-12-02 RU RU2017122758A patent/RU2721555C2/ru active
- 2015-12-02 SG SG11201704495VA patent/SG11201704495VA/en unknown
- 2015-12-02 WO PCT/US2015/063488 patent/WO2016090030A1/en not_active Ceased
- 2015-12-02 MX MX2017007000A patent/MX382116B/es unknown
- 2015-12-02 SG SG10202010594WA patent/SG10202010594WA/en unknown
- 2015-12-02 CA CA2968980A patent/CA2968980A1/en not_active Abandoned
- 2015-12-02 CN CN201580074543.0A patent/CN107206008A/zh active Pending
- 2015-12-02 KR KR1020177018195A patent/KR20170102879A/ko not_active Withdrawn
- 2015-12-02 JP JP2017527848A patent/JP6986445B2/ja not_active Expired - Fee Related
- 2015-12-02 CN CN202011279675.6A patent/CN112245419A/zh active Pending
- 2015-12-02 BR BR112017011685-5A patent/BR112017011685A2/pt not_active Application Discontinuation
-
2016
- 2016-03-07 US US15/062,636 patent/US10363235B2/en active Active
-
2017
- 2017-05-22 IL IL252431A patent/IL252431B/en unknown
- 2017-05-29 MX MX2021005080A patent/MX2021005080A/es unknown
- 2017-06-01 PH PH12017501022A patent/PH12017501022B1/en unknown
- 2017-06-30 ZA ZA2017/04463A patent/ZA201704463B/en unknown
-
2018
- 2018-06-29 ZA ZA2018/04380A patent/ZA201804380B/en unknown
-
2021
- 2021-05-18 AU AU2021203189A patent/AU2021203189A1/en not_active Abandoned
- 2021-11-10 IL IL287983A patent/IL287983A/en unknown
- 2021-11-29 JP JP2021192836A patent/JP2022031813A/ja active Pending
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2017536380A5 (OSRAM) | ||
| RU2017122758A (ru) | Композиции, содержащие 15-hepe, и способы лечения или предотвращения фиброза с применением указанных композиций | |
| Vacas et al. | High-mobility group box 1 protein initiates postoperative cognitive decline by engaging bone marrow-derived macrophages | |
| JP2014506321A5 (OSRAM) | ||
| KR20110074898A (ko) | 염증을 치료하는 방법 | |
| JP2014506928A5 (OSRAM) | ||
| JP5592262B2 (ja) | 肝細胞の増殖を誘導する方法及びその使用 | |
| JP2018532720A (ja) | 線維症の治療のためのセニクリビロック併用療法 | |
| JP2024180685A (ja) | Ｎｔｃｐ阻害剤によるアテローム性動脈硬化、原発性胆汁性肝硬変およびｎｒｌｐ３インフラマソーム関連疾患の治療 | |
| JP2015517489A5 (OSRAM) | ||
| JP6557684B2 (ja) | 線維性疾患の治療に用いられるｐｐａｒ化合物 | |
| JP2012505837A5 (OSRAM) | ||
| JP2012525393A5 (OSRAM) | ||
| JP2010502649A5 (OSRAM) | ||
| JP2018519340A5 (OSRAM) | ||
| JP2018524274A5 (OSRAM) | ||
| JP2017531673A5 (OSRAM) | ||
| JP2011502101A5 (OSRAM) | ||
| JP2017530163A5 (OSRAM) | ||
| JP2013508289A5 (OSRAM) | ||
| JP2021104999A (ja) | Ｆｘｒアゴニストの新規のレジーム | |
| JP2018503685A5 (OSRAM) | ||
| Rajani et al. | Post-infarct morphine treatment mitigates left ventricular remodeling and dysfunction in a rat model of ischemia-reperfusion | |
| JP2019526644A (ja) | Ｆｘｒアゴニストの組合せ | |
| EP3592351B1 (en) | 1-piperidinepropionic acid for treating a fibrosing disease |